Ventilator management in the age of COVID-19: response to “Logistic and organizational aspects of a dedicated intensive care unit for COVID-19 patients”

Moody, Alastair E; Beutler, Bryce D.; Antwi‐Amoabeng, Daniel; Lu, Eric; Willyard, Charles E.; Ilyas, Irtqa; Gullapalli, Nageshwara

doi:10.1186/s13054-020-03069-0

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pandemic has had an unparalleled impact on critical care resources worldwide, as systems have struggled to provide high‐quality care for a surge of critically ill patients, plan crisis surge response strategies, triage patients, and support families and staff. Logistic and organizational aspects that are required in COVID‐19 intensive care units to protect patients and healthcare workers and to protect the community at large came to the forefront 113‐115 . Given the novel and rapidly spreading nature of COVID‐19, clinicians and policy makers around the world provided urgent reviews and summaries of evidence‐based guidelines to inform practice with complimentary access to research, education, and science without having to travel for a face‐to‐face interchange 116 .…”

Section: Perspectives After the Pandemic: “The Aftermath Of The Pandementioning

confidence: 99%

Artificial lungs––Where are we going with the lung replacement therapy?

et al. 2020

View full text Add to dashboard Cite

Lung transplantation may be a final destination therapy in lung failure, but limited donor organ availability creates a need for alternative management, including artificial lung technology. This invited review discusses ongoing developments and future research pathways for respiratory assist devices and tissue engineering to treat advanced and refractory lung disease. An overview is also given on the aftermath of the coronavirus disease 2019 pandemic and lessons learned as the world comes out of this situation. The first order of business in the future of lung support is solving the problems with existing mechanical devices. Interestingly, challenges identified during the early days of development persist today. These challenges include device‐related infection, bleeding, thrombosis, cost, and patient quality of life. The main approaches of the future directions are to repair, restore, replace, or regenerate the lungs. Engineering improvements to hollow fiber membrane gas exchangers are enabling longer term wearable systems and can be used to bridge lung failure patients to transplantation. Progress in the development of microchannel‐based devices has provided the concept of biomimetic devices that may even enable intracorporeal implantation. Tissue engineering and cell‐based technologies have provided the concept of bioartificial lungs with properties similar to the native organ. Recent progress in artificial lung technologies includes continued advances in both engineering and biology. The final goal is to achieve a truly implantable and durable artificial lung that is applicable to destination therapy.

show abstract

Section: Perspectives After the Pandemic: “The Aftermath Of The Pandementioning

confidence: 99%

Artificial lungs––Where are we going with the lung replacement therapy?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…ICUs faced a paradigm shift from predominantly in-person, patient-centered care, to remote patient care and remote monitoring; these approaches minimized staff exposure to the patient and preserved the limited supply of personal protective equipment (PPE). 1 , 2 The dichotomy of in-person versus remote care was epitomized by the numerous in-person respiratory therapist (RT) interactions required to monitor and adjust ventilator settings for mechanically ventilated patients with COVID-19 respiratory failure coupled with the minimal use of remote monitoring for ventilators and the absence of remote managment solutions.…”

Section: Introductionmentioning

confidence: 99%

Novel Technology Deployed for Remote Ventilator Management by Respiratory Therapists During the COVID-19 Pandemic: Lessons Learned

Rausen

Nahass

Halpern

2022

J Intensive Care Med

View full text Add to dashboard Cite

A novel remote ventilator management (control) technology (Omnitool) was implemented for use with ICU patients during the COVID-19 pandemic to mitigate in-person respiratory therapist interactions and preserve personal protective equipment. In the latter half of 2020, eight mechanical ventilators were purchased and enabled for Omnitool deployment through the application of a vendor software option. Subsequently, these ventilators were outfitted with commercially available informatics hardware that permitted remote communication and management via the existing hospital network. In total, 17 patients with COVID-19 respiratory failure were placed on Omnitool enabled ventilators between January 1, 2021-April 30, 2021. The median Omnitool use days was 10. Deployment of a novel remote ventilator management technology is feasible; however, further study is needed to simplify the set up and utilization of the system. Future demands for remote ventilator management are predictable, whether in rural areas, military scenarios without adequate RT staffing, or in circumstances with new and easily transmissible toxic infections, and will continue to encourage the development of relatively easy to apply informatics-based solutions. Herein we share five lessons learned from our Omnitool deployment.

show abstract

Ventilator management in the age of COVID-19: response to “Logistic and organizational aspects of a dedicated intensive care unit for COVID-19 patients”

Cited by 2 publications

References 4 publications

Artificial lungs––Where are we going with the lung replacement therapy?

Artificial lungs––Where are we going with the lung replacement therapy?

Novel Technology Deployed for Remote Ventilator Management by Respiratory Therapists During the COVID-19 Pandemic: Lessons Learned

Contact Info

Product

Resources

About